Distribution record
A distribution record is a documented log or record used in the pharmaceutical industry
(and other regulated industries) to track the distribution of finished products from the
manufacturer to the final point of sale or use (e.g., wholesalers, hospitals, pharmacies).
What Is a Distribution Record?
A distribution record provides detailed information about the movement of drug
products, ensuring traceability, accountability, and compliance with Good Distribution
Practices (GDP) and Good Manufacturing Practices (GMP).
Contents of a Distribution Record
Here’s what is typically included:
Field Description
Product Name The name of the drug product
Batch/Lot Number Unique identification number assigned to the batch
Quantity Distributed Number of units/shippers/containers sent
Date of Distribution When the product was shipped out
Distributor/Customer Name To whom the product was sent (e.g., wholesaler, pharmacy)
Address of Recipient Location to which the product was delivered
Transport Method Details on how the product was shipped (truck, air, etc.)
Storage Conditions If applicable, to show cold chain was maintained
Invoice or Delivery Number Reference document for the shipment
Authorized Signature Signature of the responsible person verifying shipment
Purpose of Distribution Records
Goal Why It Matters
Traceability Tracks each batch for recalls, complaints, or investigations
Regulatory Required under GMP (21 CFR 211.196) and WHO GDP
Compliance guidelines
Recall Management Enables quick and accurate recall of defective batches
Inventory Control Supports warehouse and stock management
Customer Verification Confirms delivery to authorized customers only
Regulatory Guidelines
1. 21 CFR Part 211.196 (USA)
o
Requires distribution records to include name and strength of drug, lot
numbers, and quantity shipped.
2. WHO GDP Guidelines
o Emphasize maintaining traceability from the point of manufacture to final
delivery.
3. EU GDP Guidelines
o Require records to be retained for a defined period (usually 1 year after
product expiry).
Example Format
Dat Product Batch Quantit Recipient Addres Transpo Invoic Signatur
e No. y s rt e No. e
01- Paracetam B1234 5000 ABC New Van INV- [Signed]
Apr ol 500mg 5 tablets Distributo Delhi 10234
-25 rs
Key Points to Remember
Distribution records must be accurate, complete, and up to date.
Must be retained for a minimum period (e.g., 1–2 years post-expiry of product).
Must be available during regulatory inspections.
Helps in root cause analysis during product complaints or adverse events.
Generic Drug Product Development: A Detailed Guide
📌 What Is a Generic Drug?
A generic drug is a pharmaceutical product that is bioequivalent to a brand-name
(innovator) product in dosage form, strength, route of administration, quality,
performance, and intended use, but is typically sold at a lower price.
🔁 Goal: To replicate the therapeutic efficacy and safety of the innovator without repeating
full clinical trials.
📌 Key Objectives of Generic Development
Objective Description
Bioequivalence Demonstrate same absorption, distribution, and elimination
Quality & Safety Match impurity profile, excipients, and manufacturing quality
Regulatory Compliance Meet ANDA, ICH, WHO, EMA guidelines
Cost Efficiency Reduce R&D and clinical burden compared to brand drugs
Generic drug product development is a multi-stage process.
This focused on creating a pharmaceutical product that is equivalent to an already
approved brand-name drug.
The goal is to demonstrate bioequivalence, meaning the generic drug releases the
same amount of active ingredient into the patient's bloodstream at the same rate as the
brand-name drug.
This allows generic drugs to have the same therapeutic effect while typically being
available at a lower cost.
Reference Product → Preformulation → Formulation Development
↓ ↓
Analytical BE Study
↓ ↓
Stability Studies → ANDA Submission → Approval → Launch
Here's a detailed breakdown of the generic drug product development process:
1. Identification and Feasibility Analysis:
Identify Healthcare Needs and Market Opportunity: This involves analyzing the
market for potential generic drugs, considering factors like the patent expiry of
branded drugs, market size, and the need for affordable alternatives.
Reference Listed Drug (RLD) Selection: The generic drug developer identifies the
specific branded drug they intend to replicate.
Patent and Exclusivity Assessment: Thoroughly investigate the patent status and
any market exclusivity periods of the RLD to ensure market entry is legally
permissible.
API Sourcing and Cost Analysis: Identify sources for the Active Pharmaceutical
Ingredient (API) and other excipients, and conduct a cost-benefit analysis.
Regulatory Landscape Assessment: Understand the specific regulatory
requirements and guidelines in the target market (e.g., FDA in the United States,
CDSCO in India, EMA in Europe).
2. Pre-Formulation Studies and Formulation Development:
RLD Characterization: In-depth analysis of the RLD's composition, physical and
chemical properties, formulation, and performance characteristics..
API Characterization: Comprehensive study of the API's properties, including
solubility, stability, particle size, polymorphism, and hygroscopicity.
Excipient Selection and Compatibility Studies: Choosing excipients that are safe,
compatible with the API, and help in achieving the desired drug product performance.
Compatibility studies are conducted to ensure no adverse interactions between the
API and excipients.
Formulation Design: Developing the formulation of the generic drug product,
considering factors like dosage form (tablets, capsules, solutions, etc.), strength,
release profile (immediate release, modified release).
Analytical Method Development: Developing and validating robust analytical
methods to test the quality, purity, strength, and stability of the generic drug product
and its components.
3. Manufacturing Process Development and Optimization:
Process Development: Designing a scalable and reproducible manufacturing process
for the generic drug product. This includes unit operations like blending, granulation,
compression (for tablets), filling (for capsules), and coating.
Process Optimization: Refining the manufacturing process parameters to ensure
consistent product quality, yield, and efficiency at a commercial scale.
Process Validation: validate the established manufacturing process consistently
produces a product meeting predetermined quality attributes.
Stability Studies: Conducting stability studies under various storage conditions
(temperature, humidity, light) to determine the shelf life of the generic drug product.
4. Bioequivalence (BE) Studies:
Study Design: Designing a bioequivalence study to compare the rate and extent of
absorption of the generic drug to the branded drug.
Pharmacokinetic (PK) Analysis: Measuring the concentration of the API in the
volunteers' blood or plasma at various time points and analyzing pharmacokinetic
parameters such as:
o AUC (Area Under the Curve): Represents the total drug exposure.
o Cmax (Maximum Concentration): Represents the rate of absorption.
o Tmax (Time to Maximum Concentration): Represents the time at which
Cmax is reached.
Statistical Analysis: AUC and Cmax for the generic to the RLD should typically fall
within the acceptance range of 80.00% to 125.00%.
4. Regulatory Submission and Approval:
6. Post-Approval Activities:
Manufacturing and Quality Control
Pharmacovigilance:
Post-Market Surveillance:
Challenges in Generic Drug Development:
Regulatory Complexity: Navigating the complex and evolving regulatory
requirements of different countries.
Bioequivalence Testing: Designing and conducting successful bioequivalence
studies, especially for complex formulations.
Formulation Complexity: Replicating the exact formulation and performance of
complex brand-name drugs, such as modified-release products, injectables, and
inhalers.
Pricing Pressures: Balancing the need for affordability with the costs of
development, manufacturing, and regulatory compliance in a highly competitive
market.
Quality Issues: Maintaining high-quality standards and adhering to GMP throughout
the manufacturing process.